These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 30102294)

  • 1. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria.
    Isabella VM; Ha BN; Castillo MJ; Lubkowicz DJ; Rowe SE; Millet YA; Anderson CL; Li N; Fisher AB; West KA; Reeder PJ; Momin MM; Bergeron CG; Guilmain SE; Miller PF; Kurtz CB; Falb D
    Nat Biotechnol; 2018 Oct; 36(9):857-864. PubMed ID: 30102294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering.
    Adolfsen KJ; Callihan I; Monahan CE; Greisen PJ; Spoonamore J; Momin M; Fitch LE; Castillo MJ; Weng L; Renaud L; Weile CJ; Konieczka JH; Mirabella T; Abin-Fuentes A; Lawrence AG; Isabella VM
    Nat Commun; 2021 Oct; 12(1):6215. PubMed ID: 34711827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.
    Puurunen MK; Vockley J; Searle SL; Sacharow SJ; Phillips JA; Denney WS; Goodlett BD; Wagner DA; Blankstein L; Castillo MJ; Charbonneau MR; Isabella VM; Sethuraman VV; Riese RJ; Kurtz CB; Brennan AM
    Nat Metab; 2021 Aug; 3(8):1125-1132. PubMed ID: 34294923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of phenylalanine ammonia lyase as an intracellularly free and extracellularly cell surface-immobilized enzyme on a gut microbe as a live biotherapeutic for phenylketonuria.
    Jiang Y; Sun B; Qian F; Dong F; Xu C; Zhong W; Huang R; Zhai Q; Jiang Y; Yang S
    Sci China Life Sci; 2023 Jan; 66(1):127-136. PubMed ID: 35907113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria.
    Charbonneau MR; Denney WS; Horvath NG; Cantarella P; Castillo MJ; Puurunen MK; Brennan AM
    Commun Biol; 2021 Jul; 4(1):898. PubMed ID: 34294862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU).
    Hamman KJ; Winn SR; Harding CO
    Mol Genet Metab; 2011 Nov; 104(3):235-40. PubMed ID: 21917493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redesign of an Escherichia coli Nissle treatment for phenylketonuria using insulated genomic landing pads and genetic circuits to reduce burden.
    Triassi AJ; Fields BD; Monahan CE; Means JM; Park Y; Doosthosseini H; Padmakumar JP; Isabella VM; Voigt CA
    Cell Syst; 2023 Jun; 14(6):512-524.e12. PubMed ID: 37348465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial.
    Vockley J; Sondheimer N; Puurunen M; Diaz GA; Ginevic I; Grange DK; Harding C; Northrup H; Phillips JA; Searle S; Thomas JA; Zori R; Denney WS; Ernst SL; Humphreys K; McWhorter N; Kurtz C; Brennan AM
    Nat Metab; 2023 Oct; 5(10):1685-1690. PubMed ID: 37770764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut-Microbiome Composition in Response to Phenylketonuria Depends on Dietary Phenylalanine in BTBR Pah
    van der Goot E; Vink SN; van Vliet D; van Spronsen FJ; Falcao Salles J; van der Zee EA
    Front Nutr; 2021; 8():735366. PubMed ID: 35059423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip.
    Nelson MT; Charbonneau MR; Coia HG; Castillo MJ; Holt C; Greenwood ES; Robinson PJ; Merrill EA; Lubkowicz D; Mauzy CA
    Nat Commun; 2021 May; 12(1):2805. PubMed ID: 33990606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pah(enu2) mice.
    Embury JE; Charron CE; Martynyuk A; Zori AG; Liu B; Ali SF; Rowland NE; Laipis PJ
    Brain Res; 2007 Jan; 1127(1):136-50. PubMed ID: 17112485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer.
    Ding Z; Georgiev P; Thöny B
    Gene Ther; 2006 Apr; 13(7):587-93. PubMed ID: 16319947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma phenylalanine concentrations are associated with hepatic iron content in a murine model for phenylketonuria.
    Gropper SS; Yannicelli S; White BD; Medeiros DM
    Mol Genet Metab; 2004 May; 82(1):76-82. PubMed ID: 15110326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive effect of a simplified diet on blood phenylalanine control in different phenylketonuria variants, characterized by newborn BH4 loading test and PAH analysis.
    Zimmermann M; Jacobs P; Fingerhut R; Torresani T; Thöny B; Blau N; Baumgartner MR; Rohrbach M
    Mol Genet Metab; 2012 Jul; 106(3):264-8. PubMed ID: 22607939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).
    Winn SR; Scherer T; Thöny B; Harding CO
    Mol Genet Metab; 2016 Jan; 117(1):5-11. PubMed ID: 26653793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.
    Harding CO; Gillingham MB; Hamman K; Clark H; Goebel-Daghighi E; Bird A; Koeberl DD
    Gene Ther; 2006 Mar; 13(5):457-62. PubMed ID: 16319949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creatine energy substrate increases bone density in the Pah
    Dobrowolski SF; Tourkova IL; Larrouture QC; Blair HC
    Mol Genet Metab Rep; 2023 Sep; 36():100996. PubMed ID: 37588420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term correction of murine phenylketonuria by viral gene transfer: liver versus muscle.
    Thöny B
    J Inherit Metab Dis; 2010 Dec; 33(6):677-80. PubMed ID: 20151201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex effects of dietary protein source and acid load on renal and bone status in the Pah
    Stroup BM; Murali SG; Schwahn DJ; Sawin EA; Lankey EM; Bächinger HP; Ney DM
    Physiol Rep; 2019 Oct; 7(20):e14251. PubMed ID: 31650703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?
    Sarkissian CN; Gámez A
    Mol Genet Metab; 2005 Dec; 86 Suppl 1():S22-6. PubMed ID: 16165390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.